loading
Schlusskurs vom Vortag:
$0.5266
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.58M
KGV:
0.00
EPS:
-0.76
Netto-Cashflow:
$-26.63M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
Value
$0.00
$0.00
1-Wochen-Bereich:
Value
$0.00
$0.00
52-Wochen-Spanne:
Value
$0.00
$11.45

Oncternal Therapeutics Inc Stock (ONCT) Company Profile

Name
Firmenname
Oncternal Therapeutics Inc
Name
Telefon
(858) 434-1113
Name
Adresse
12230 EL CAMINO REAL, SAN DIEGO, CA
Name
Mitarbeiter
27
Name
Twitter
@oncternal
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ONCT's Discussions on Twitter

Vergleichen Sie ONCT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ONCT
Oncternal Therapeutics Inc
0.00 1.56M 0 -34.58M -26.63M -11.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
402.70 103.71B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
712.33 78.28B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
615.00 36.77B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.31 30.35B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.95 27.32B 3.30B -501.07M 1.03B -2.1146

Oncternal Therapeutics Inc Stock (ONCT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-04-07 Eingeleitet Oppenheimer Outperform
2021-02-23 Eingeleitet Northland Capital Outperform

Oncternal Therapeutics Inc Aktie (ONCT) Neueste Nachrichten

pulisher
Dec 29, 2024

Oncternal Therapeutics (NASDAQ:ONCT) Now Covered by Analysts at StockNews.com - Defense World

Dec 29, 2024
pulisher
Dec 21, 2024

Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com - Defense World

Dec 21, 2024
pulisher
Dec 19, 2024

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference - Marketscreener.com

Dec 19, 2024
pulisher
Dec 10, 2024

CELUCelularity Inc. Latest Stock News & Market Updates - StockTitan

Dec 10, 2024
pulisher
Dec 05, 2024

Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com - Defense World

Dec 05, 2024
pulisher
Dec 02, 2024

ONCT stock touches 52-week low at $0.61 amid market challenges - Investing.com Australia

Dec 02, 2024
pulisher
Dec 02, 2024

ONCT stock touches 52-week low at $0.61 amid market challenges By Investing.com - Investing.com South Africa

Dec 02, 2024
pulisher
Nov 27, 2024

StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT) - Defense World

Nov 27, 2024
pulisher
Nov 26, 2024

ONCT stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa

Nov 26, 2024
pulisher
Nov 25, 2024

ONCT stock touches 52-week low at $0.83 amid market challenges - Investing.com

Nov 25, 2024
pulisher
Nov 25, 2024

Oncternal shares to be delisted from Nasdaq - Investing.com

Nov 25, 2024
pulisher
Nov 20, 2024

Oncternal Therapeutics Reports Q3 2024 Earnings - TipRanks

Nov 20, 2024
pulisher
Nov 20, 2024

ONCT (Oncternal Therapeutics) 9-Day RSI : 33.20 (As of Nov. 20, 2024) - GuruFocus.com

Nov 20, 2024
pulisher
Nov 15, 2024

Oncternal announces workforce reduction, executive changes - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Oncternal Therapeutics to Cut Most of Its Workforce - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Oncternal Therapeutics Announces Workforce Reduction and Executive Changes - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

ONCT Stock Touches 52-Week Low at $1.03 Amid Market Challenges - Investing.com

Nov 14, 2024
pulisher
Nov 07, 2024

Phase 1/2 trial of ONCT-534 in mCRPC has been terminated - Urology Times

Nov 07, 2024
pulisher
Oct 30, 2024

Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer - Marketscreener.com

Oct 30, 2024
pulisher
Oct 23, 2024

Oncternal reports positive prostate cancer treatment results By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 22, 2024

Oncternal reports positive prostate cancer treatment results - Investing.com India

Oct 22, 2024
pulisher
Oct 22, 2024

Oncternal Therapeutics Announces Updated Safety and - GlobeNewswire

Oct 22, 2024
pulisher
Oct 18, 2024

B-Cell Non-Hodgkin Lymphoma Pipeline Assessment 2024: Therapies, Clinical Trials, and Growth Prospects | Biegene, Oncternal Therapeutics, ZAI Lab, Pfizer, Xynomic Pharma, SystImmune Inc., Autolus - Barchart

Oct 18, 2024
pulisher
Oct 11, 2024

ONCT Stock Touches 52-Week Low at $1.19 Amid Market Challenges - Investing.com Australia

Oct 11, 2024
pulisher
Oct 09, 2024

Oncternal Therapeutics Inc (ONCT) Q2 2024 Earnings Call Highlights: Advancements in Clinical ... - Yahoo Finance Australia

Oct 09, 2024
pulisher
Oct 03, 2024

Oncternal stock jumps 9% on FDA fast track designation - MSN

Oct 03, 2024
pulisher
Oct 01, 2024

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.58% - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges - Investing.com Australia

Sep 30, 2024
pulisher
Sep 30, 2024

ONCT Stock Touches 52-Week Low at $1.31 Amid Market Challenges By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 27, 2024

Recent Research Analysts’ Ratings Changes for Oncternal Therapeutics (ONCT) - Defense World

Sep 27, 2024
pulisher
Sep 25, 2024

Omnicell Appoints Nnamdi Njoku as New COO - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Oncolytics Biotech (TSE:ONC) Reaches New 12-Month Low at $1.20 - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

ONON’s Stock Market Adventure: 85.15% YTD Growth Amidst Volatility - The InvestChronicle

Sep 25, 2024
pulisher
Sep 25, 2024

Omnicell Appoints Nnamdi Njoku as Executive Vice President and Chief Operating Officer - Silicon UK

Sep 25, 2024
pulisher
Sep 25, 2024

ONMD’s price-to-free cash flow ratio: How it affects investment decisions - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Levi & Korsinsky Notifies Shareholders of Outset Medical, - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Outset Medical, Inc.OM - PR Newswire

Sep 25, 2024
pulisher
Sep 25, 2024

Fred Alger Management LLC Has $44.73 Million Position in On Holding AG (NYSE:ONON) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace

Sep 25, 2024
pulisher
Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Outset Medical Inc (OM) - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

On Holding's Options Frenzy: What You Need to Know - Benzinga

Sep 24, 2024
pulisher
Sep 24, 2024

This Option Provides Gains By Coasting With On Running Shoes - Investor's Business Daily

Sep 24, 2024
pulisher
Sep 24, 2024

ONON’s valuation metrics: A comprehensive analysis - US Post News

Sep 24, 2024
pulisher
Sep 24, 2024

OM Stock on the Rise: A Promising Investment - The InvestChronicle

Sep 24, 2024
pulisher
Sep 24, 2024

Was Outset Medical Inc (OM)’s session last reading good? - US Post News

Sep 24, 2024
pulisher
Sep 24, 2024

Promising Progress in Oncology as Cancer Deaths Decline and Research Grows - Baystreet.ca

Sep 24, 2024
pulisher
Sep 24, 2024

Views of Wall Street’s Leading Experts on Onconetix Inc - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Financial Metrics Unveiled: Outset Medical Inc (OM)’s Key Ratios in the Spotlight - The Dwinnex

Sep 24, 2024
pulisher
Sep 23, 2024

Outset Medical (OM) Shares Down 94% Since Disclosing FDA - GlobeNewswire

Sep 23, 2024

Finanzdaten der Oncternal Therapeutics Inc-Aktie (ONCT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.87
price up icon 0.48%
$69.07
price up icon 0.95%
$352.84
price down icon 1.34%
$41.58
price up icon 5.59%
$184.71
price up icon 0.49%
$113.95
price up icon 1.22%
Kapitalisierung:     |  Volumen (24h):